Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Fish and Richardson
Chubb
Boehringer Ingelheim
Daiichi Sankyo
Merck
UBS
Harvard Business School
Julphar

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,652,776

« Back to Dashboard

Which drugs does patent 8,652,776 protect, and when does it expire?

Patent 8,652,776 protects FANAPT and is included in one NDA.

This patent has five patent family members in four countries.
Summary for Patent: 8,652,776
Title:Prediction of QT prolongation based on SNP genotype
Abstract: The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
Inventor(s): Lavedan; Christian (Potomac, MD), Volpi; Simona (Derwood, MD), Licamele; Louis (Gaithersburg, MD), Mack; Kendra Tomino (Westminster, MD), Heaton; Callie Michelle (Washington, DC)
Assignee: Vanda Pharmaceuticals, Inc. (Washington, DC)
Application Number:12/675,607
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,652,776

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-001 May 6, 2009 AB RX Yes Yes ➤ Sign Up ➤ Sign Up DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ➤ Sign Up
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-002 May 6, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ➤ Sign Up
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-003 May 6, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ➤ Sign Up
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-004 May 6, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,652,776

PCT Information
PCT FiledSeptember 10, 2008PCT Application Number:PCT/US2008/075905
PCT Publication Date:March 19, 2009PCT Publication Number: WO2009/036100

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Julphar
Dow
Express Scripts
Accenture
Merck
Federal Trade Commission
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.